Gordagen Pharmaceuticals

About

Gordagen is a Melbourne-based developer and commercializer of tocotrienol-based nutraceuticals and prescription medicines using a proprietary MELT3 “melt-then-swallow” tissue-targeting delivery system for heart health and exercise recovery.

Mission

Gordagen develops and commercializes tocotrienol-based nutraceuticals and prescription medicines, focusing initially on heart health, muscle soreness and exercise endurance. The company uses a proprietary, patent-pending MELT3™ ‘‘melt-then-swallow’’ delivery technology to target tissues with highly potent tocotrienols. Gordagen planned a US launch of its first product, nE1-Heart™, in the first half of calendar year 2016 and aimed to begin phase II studies in the US for nE1-ElitE™ in the same period. Management is preparing to expand on-ground commercial support in the US and pursue strategic partnering in Japan. The company is privately held and operating from Melbourne, Australia, and is transitioning from R&D toward commercial operations. Gordagen also announced governance changes, including the chairman moving to a Special Advisor role and plans to add at least two independent non-executive directors by end of Q1 2016.

Quick Facts